Aia Group LTD Alnylam Pharmaceuticals, Inc. Transaction History

Aia Group LTD

$4.23 Billion
Q2 2025

A detailed history of Aia Group LTD transactions in Alnylam Pharmaceuticals, Inc. stock. As of the latest transaction made, Aia Group LTD holds 30,232 shares of ALNY stock, worth $13.6 Million. This represents 0.23% of its overall portfolio holdings.

Number of Shares

30,232

Previous 26,491 14.12%

Holding current value

$13.6 Million

Previous $7.15 Million 37.82%

% of portfolio

0.23%

Previous 0.19%

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2025 Aug 06, 2025	BUY	$224.32 - $326.09 $839,181 - $1.22 Million	3,741 Added 14.12%	30,232 $9.86 Million
Q1 2025 May 12, 2025	BUY	$233.07 - $290.7 $849,074 - $1.06 Million	3,643 Added 15.94%	26,491 $7.15 Million
Q4 2024 Feb 12, 2025	SELL	$232.27 - $300.43 $1.25 Million - $1.61 Million	-5,369 Reduced 19.03%	22,848 $5.38 Million
Q3 2024 Oct 31, 2024	BUY	$233.81 - $287.01 $2.05 Million - $2.52 Million	8,789 Added 45.24%	28,217 $7.76 Million
Q2 2024 Jul 31, 2024	BUY	$143.31 - $247.0 $685,595 - $1.18 Million	4,784 Added 32.67%	19,428 $4.72 Million
Q3 2023 Nov 01, 2023	BUY	$170.77 - $211.65 $350,078 - $433,882	2,050 Added 16.28%	14,644 $2.59 Million
Q2 2023 Jul 28, 2023	BUY	$185.01 - $212.05 $1.28 Million - $1.47 Million	6,910 Added 121.57%	12,594 $2.39 Million
Q1 2023 Apr 28, 2023	BUY	$182.66 - $235.53 $125,122 - $161,338	685 Added 13.7%	5,684 $1.14 Million
Q4 2022 Jan 31, 2023	BUY	$185.53 - $241.31 $199,444 - $259,408	1,075 Added 27.4%	4,999 $1.19 Million
Q3 2022 Nov 04, 2022	BUY	$138.54 - $232.0 $143,943 - $241,048	1,039 Added 36.01%	3,924 $785,000
Q2 2022 Aug 11, 2022	BUY	$120.42 - $169.29 $347,411 - $488,401	2,885 New	2,885 $421,000

Others Institutions Holding ALNY

# of Institutions

806

Shares Held

116M

Call Options Held

584K

Put Options Held

648K

View Full List

About ALNYLAM PHARMACEUTICALS, INC.

Ticker ALNY
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 123,028,000
Market Cap $55.3B
Description
Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. The company's pipeline of investigational RNAi therapeutics focuses on genetic medicines, cardio-metabolic diseases, hepatic infectious diseases, and central nervous system...

More about ALNY

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Aia Group LTD, based on Form 13F filings with the SEC.

News

Stay updated on Aia Group LTD with notifications on news.

Account